|
|
Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufacture APIs in oncology and other therapeutic areas.
Laurus Labs operates in four business lines:
1. Generics active pharmaceutical ingredients (APIs) - The development, manufacture and sale of APIs and advanced intermediates.
2. Generics finished dosage forms (FDFs) - The development and manufacture of oral solid formulations.
3. Synthesis - Contract development and manufacturing services for global pharmaceutical companies.
4. Ingredients - The manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors.
Key Highlights:
1. Laurus Labs launched 59 products since our inception in 2005.
2. Nine out of the 10 largest generic pharmaceutical companies in the world are its customers.
3. Laurus Labs employed 587 scientists at our R&D center in Hyderabad and 12 scientists at R&D centre in Greater Boston USA.
4. The Company owned 32 patents and had 150 pending patent applications, in several countries.
5. Company has three manufacturing facilities in Visakhapatnam, Andhra Pradesh.
6. Company sells its products in 32 countries in Sub-Saharan Africa, South-East Asia and Latin America.
Key Strengths:
1. Leadership in APIs in Select, High Growth Therapeutic Areas
2. Strong R&D Capabilities and Process Chemistry Skills
3. Industry Leading, Modern and Regulatory Compliant Manufacturing Capacities
4. Long-standing Relationships with Multi-National Pharmaceutical Companies
5. Experienced Promoters and Qualified Operational Personnel
6. Established Track Record of Delivering Growth
The Promoters of the company are:
1. Dr Satyanarayana Chava
2. Naga Rani Chava
3. Dr Raju Srihari Kalidindi
4. Ravi Kumar V V and
5. Dr Lakshmana Rao C V
| Particulars | For the year/period ended (in Rs. Million) | ||||
|---|---|---|---|---|---|
| 31-Mar-16 | 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 | |
| Total Assets | 23,083.48 | 18,925.49 | 12,730.58 | 7,009.89 | 5,128.78 |
| Total Revenue | 17,884.15 | 13,603.80 | 11,685.34 | 7,235.67 | 4,523.07 |
| Profit After Tax (PAT) | 1,435.68 | 735.17 | 972.17 | 882.19 | 215.77 |
The object of the issue are to:
1. Pre-payment of term loans; and
2. General corporate purposes.
| IPO Opening Date | Dec 6, 2016 |
| IPO Closing Date | Dec 8, 2016 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹10 per equity share |
| IPO Price | ₹426 to ₹428 per equity share |
| Market Lot | 35 Shares |
| Min Order Quantity | 35 Shares |
| Listing At | BSE, NSE |
| Issue Size | 31,116,785 Eq Shares of ₹10 (aggregating up to ₹1,331.80 Cr) |
| Fresh Issue | 7,009,345 Eq Shares of ₹10 (aggregating up to ₹300.00 Cr) |
| Offer for Sale | 24,107,440 Eq Shares of ₹10 (aggregating up to ₹1,031.80 Cr) |
The Laurus Labs IPO open date is Dec 6, 2016, and the close date is Dec 8, 2016. The issue may list on Dec 19, 2016.
| IPO Open Date | Dec 6, 2016 |
| IPO Close Date | Dec 8, 2016 |
| Basis of Allotment Date | Dec 14, 2016 |
| Initiation of Refunds | Dec 15, 2016 |
| Credit of Shares to Demat Account | Dec 16, 2016 |
| IPO Listing Date | Dec 19, 2016 |
The Laurus Labs IPO market lot size is 35 shares. A retail-individual investor can apply for up to 13 lots (455 shares or ₹194,740).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 35 | ₹14,980 |
| Maximum | 13 | 455 | ₹194,740 |
Company is having good contracts from world leaders and enjoys leadership position in APIs and generics. Investments made by the company will start adding to revenues and profits from FY 18 onwards and thus poised for bright prospects. Although issue appears to have been priced in line with peer’s trending, it may be considered for medium to long term investment. Read detail review...
The Laurus Labs IPO is subscribed 4.53 times on 12/8/2016 6:18:00 PM. The public issue subscribed 1.58 times in the retail category, 10.54 times in the QIB category, and 3.57 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 10.54 |
| NII | 3.57 |
| Retail | 1.58 |
| Employee | 1.71 |
| Total | 4.53 |
| Listing Date | Monday, December 19, 2016 |
| BSE Script Code | 540222 |
| NSE Symbol | LAURUSLABS |
| Listing In | B Group of Securities |
| ISIN | INE947Q01010 |
| IPO Price | ₹428 per equity share |
| Face Value | ₹10 per equity share |
|
|
|
Laurus Labs Ltd
Plot No.21,
Jawaharlal Nehru Pharma City,
Parawada, Visakhapatnam 531 021
Phone: + 91 40 3980 4333
Email: secretarial@lauruslabs.com
Website: http://www.lauruslabs.com
KFintech Private Limited
Phone: 04067162222, 04079611000
Email: einward.ris@karvy.com
Website: https://karisma.kfintech.com/
Laurus Labs IPO is a main-board IPO of 31,116,785 equity shares of the face value of ₹10 aggregating up to ₹1,331.80 Crores. The issue is priced at ₹426 to ₹428 per equity share. The minimum order quantity is 35 Shares.
The IPO opens on Dec 6, 2016, and closes on Dec 8, 2016.
KFintech Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Laurus Labs IPO opens on Dec 6, 2016 and closes on Dec 8, 2016.
Laurus Labs IPO lot size is 35 Shares and the minimum order quantity is 35 Shares.
You can apply in Laurus Labs IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Laurus Labs IPO will be done on Dec 14, 2016, and the allotted shares will be credited to your demat account by Dec 16, 2016. Check the Laurus Labs IPO allotment status.
Useful Articles
Top Contributor (200+ Posts, 300+ Likes)
IPO Mentor (900+ Posts, 700+ Likes)
IPO Guru (1600+ Posts, 3900+ Likes)
